More about

Insulin Aspart

News
August 15, 2024
4 min read
Save

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

News
April 29, 2024
3 min read
Save

Missing insulin doses linked to lower time in range for adults with diabetes

Missing insulin doses linked to lower time in range for adults with diabetes

Adults with diabetes who use a smart pen for both basal and bolus insulin delivery have a reduction in time in range with each injection they miss over a 14-day period, according to data published in Diabetes Care.

News
January 08, 2024
2 min read
Save

Combination insulin icodec and semaglutide cuts HbA1c and body weight in type 2 diabetes

Combination insulin icodec and semaglutide cuts HbA1c and body weight in type 2 diabetes

Once-weekly combination therapy of basal insulin icodec and semaglutide was noninferior to insulin glargine plus insulin aspart for lowering HbA1c among adults with type 2 diabetes, according to topline results from a phase 3a trial.

News
May 08, 2023
3 min read
Save

Time in range similar with fast-acting vs. standard insulin for young kids with diabetes

Time in range similar with fast-acting vs. standard insulin for young kids with diabetes

Fast-acting insulin aspart delivered through a hybrid closed-loop insulin delivery system provided similar glycemic outcomes as standard insulin aspart for young children with type 1 diabetes, according to study data.

News
March 14, 2023
2 min read
Save

Novo Nordisk to cut prices by up to 75% for some insulin products in 2024

Novo Nordisk to cut prices by up to 75% for some insulin products in 2024

Novo Nordisk is the latest company to announce a large reduction in insulin prices as it stated it will cut prices for multiple insulin products by up to 75% in 2024.

News
November 12, 2021
2 min read
Save

Fast-acting insulin, insulin aspart provide similar glycemic control after exercise

Fast-acting insulin, insulin aspart provide similar glycemic control after exercise

Fast-acting insulin aspart provides similar time in range as insulin aspart for adults with type 1 diabetes engaging in moderate- or high-intensity exercise, according to study findings published in Diabetes Technology & Therapeutics.

News
July 07, 2021
1 min read
Save

Top in endocrinology: Walmart’s private brand analog insulin, new data on tirzepatide

Top in endocrinology: Walmart’s private brand analog insulin, new data on tirzepatide

Walmart announced that insulin aspart injections are now available through its private ReliOn brand, with doses discounted from 58% to 75% off other insulin products. The announcement was the top story in endocrinology last week.

News
July 01, 2021
3 min read
Save

Walmart launches first and only private brand analog insulin

Walmart launches first and only private brand analog insulin

Walmart announced it will partner with Novo Nordisk to launch a first-ever private brand analog insulin, retailing up to 75% off the cash price of branded insulin products, according to a press release.

News
July 01, 2021
2 min read
Save

Pramlintide-insulin co-formulation improves time in range in type 1 diabetes

Pramlintide-insulin co-formulation improves time in range in type 1 diabetes

ADO09, a co-formulation of pramlintide and insulin A21G, was associated with better glucose levels, improved time in range and more weight loss among people with type 1 diabetes compared with insulin aspart, according to a presenter.

News
February 07, 2020
2 min read
Save

Insulin aspart biosimilar safe for pump therapy use in type 1 diabetes

Insulin aspart biosimilar safe for pump therapy use in type 1 diabetes

A follow-on therapy to insulin aspart was shown to be safe and effective for pump use among adults with type 1 diabetes, with no increased incidence of unexplained hypoglycemia when compared with the reference product, according to findings from an open-label crossover study published in Diabetes Technology & Therapeutics.

View more